Non-Alzheimer's amnestic mild cognitive impairment with medial temporal hypometabolism.

IF 4 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2024-10-23 eCollection Date: 2024-10-01 DOI:10.1002/dad2.70018

Sebastiaan De Keersmaecker, Steffi De Meyer, Rik Vandenberghe

{"title":"Non-Alzheimer's amnestic mild cognitive impairment with medial temporal hypometabolism.","authors":"Sebastiaan De Keersmaecker, Steffi De Meyer, Rik Vandenberghe","doi":"10.1002/dad2.70018","DOIUrl":null,"url":null,"abstract":"Introduction: The increasing use of Alzheimer's disease (AD) biomarkers has led to the recognition of a subgroup of non-AD amnestic mild cognitive impairment (aMCI) patients who have medial temporal hypometabolism on fluorodeoxyglucose-positron emission tomography (FDG-PET).Methods: In this academic memory-clinic-based consecutive series, 16 non-AD aMCI patients and 28 AD controls matched for sex, age, and baseline Mini-Mental State Examination (MMSE) were followed for a median duration of 4.5 years. Our primary outcome was the MMSE decline rate over the subsequent years. We also determined the final diagnosis over time.Results: FDG-PET showed more pronounced medial temporal hypometabolism in non-AD cases and more inferior parietal lobule hypometabolism in AD controls. MMSE decline was slower in non-AD (β = -0.51) than in AD (β = -2.00) patients. Five non-AD cases developed frontotemporal dementia years after symptom onset, and one developed dementia with Lewy bodies.Discussion: Non-AD aMCI patients with medial temporal hypometabolism show slower cognitive decline.Highlights: Non-AD aMCI with medial temporal hypometabolism shows slower cognitive decline than AD.FDG-PET revealed distinct metabolic patterns between non-AD aMCI and AD patients.Approximately one-third of non-AD aMCI cases developed frontotemporal dementia.Comprehensive diagnostic biomarkers are crucial for non-AD aMCI characterization.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"16 4","pages":"e70018"},"PeriodicalIF":4.0000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497174/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The increasing use of Alzheimer's disease (AD) biomarkers has led to the recognition of a subgroup of non-AD amnestic mild cognitive impairment (aMCI) patients who have medial temporal hypometabolism on fluorodeoxyglucose-positron emission tomography (FDG-PET).

Methods: In this academic memory-clinic-based consecutive series, 16 non-AD aMCI patients and 28 AD controls matched for sex, age, and baseline Mini-Mental State Examination (MMSE) were followed for a median duration of 4.5 years. Our primary outcome was the MMSE decline rate over the subsequent years. We also determined the final diagnosis over time.

Results: FDG-PET showed more pronounced medial temporal hypometabolism in non-AD cases and more inferior parietal lobule hypometabolism in AD controls. MMSE decline was slower in non-AD (β = -0.51) than in AD (β = -2.00) patients. Five non-AD cases developed frontotemporal dementia years after symptom onset, and one developed dementia with Lewy bodies.

Discussion: Non-AD aMCI patients with medial temporal hypometabolism show slower cognitive decline.

Highlights: Non-AD aMCI with medial temporal hypometabolism shows slower cognitive decline than AD.FDG-PET revealed distinct metabolic patterns between non-AD aMCI and AD patients.Approximately one-third of non-AD aMCI cases developed frontotemporal dementia.Comprehensive diagnostic biomarkers are crucial for non-AD aMCI characterization.

查看原文本刊更多论文

非阿尔茨海默氏症伴有内侧颞叶代谢低下的轻度认知障碍。

导言：随着阿尔茨海默病（AD）生物标志物的应用日益广泛，人们认识到在非AD伴有轻度认知障碍（aMCI）的患者中，有一个亚群在氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）中发现颞叶内侧代谢减低：在这个以学术记忆诊所为基础的连续系列研究中，我们对16名非AD aMCI患者和28名AD对照者进行了中位持续时间为4.5年的随访，这些患者的性别、年龄和基线精神状态检查（MMSE）均匹配。我们的主要结果是随后几年的 MMSE 下降率。我们还确定了随着时间推移的最终诊断结果：结果：FDG-PET显示，非AD病例的颞叶内侧代谢减低更明显，而AD对照组的顶叶下叶代谢减低更明显。非 AD 患者的 MMSE 下降速度（β = -0.51）慢于 AD 患者（β = -2.00）。5例非AD患者在症状出现多年后发展为额颞叶痴呆，1例发展为路易体痴呆：讨论：患有内侧颞叶代谢减低症的非AD aMCI患者认知能力下降较慢：FDG-PET显示了非AD aMCI和AD患者之间截然不同的代谢模式，约三分之一的非AD aMCI病例发展为额颞叶痴呆。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.